Nemaura Med Inc Stock Price, News & Analysis

Nemaura Medical Inc. (NASDAQ: NMRD) reported its fiscal Q3 2021 results, ending December 31, 2020, with a net loss of $1.45 million, compared to $445,000 the previous year. The company raised $20 million in non-dilutive funding and has a cash balance of $33 million as of February 15, 2021. Key developments include launching the beatdiabetes.life program and positive feedback from sugarBEAT users. R&D expenses decreased to $487,000, aligning with the product nearing commercial launch. Nemaura's market strategy targets the growing diabetes sector, projected to reach $59 billion by 2025.

Nemaura Medical (Nasdaq: NMRD) announced a significant financing milestone on February 11, 2021. The company secured a $20 million non-dilutive loan backed by its assets, increasing its cash reserves to over $34 million. This amount is substantially above its quarterly burn rate of $1.5 million, providing essential financial flexibility. CEO Dr. Faz Chowdhury highlighted that this financing will fuel the company's growth without diluting shareholder equity. Nemaura focuses on non-invasive diagnostic devices and has key products like sugarBEAT® and proBEAT™.

Nemaura Medical (Nasdaq: NMRD) announces the appointment of Thomas Mortensen as head of E.U. commercial operations and marketing. With over 25 years in the medical device sector, notably at Roche Diabetes Care, Mortensen is expected to enhance the company's marketing strategy for its direct-to-consumer products in Europe. Nemaura is advancing its sugarBEAT® continuous glucose monitor and preparing to launch proBEAT™ in the U.S. The diabetes market is projected to reach approximately $59 billion by 2025, positioning Nemaura for significant growth.

Nemaura Medical (NASDAQ: NMRD) has appointed Jay L. Warner as the head of U.S. commercial operations. With over 30 years in healthcare, Warner's expertise includes developing wearable devices for diabetes management. CEO Faz Chowdhury highlighted the significant market opportunity, as currently less than one million of the 25 million diabetes patients are effectively managed, despite the rise of telemedicine. With the integration of the BEATdiabetes program, the company aims to cater to diabetes and pre-diabetes populations. Nemaura continues developing its CE-marked sugarBEAT® device, enhancing its position in the $59 billion diabetes market.

Nemaura Medical, a medical technology company, will have CEO Faz Chowdhury present at the H.C. Wainwright Bioconnect 2021 Virtual Conference from January 11-14, 2021. The presentation is accessible on-demand starting January 11 at 6:00 AM ET. Nemaura specializes in non-invasive wearable diagnostic devices, including sugarBEAT®, a continuous glucose monitor that aids diabetes management. The company targets the rapidly growing Type 2 diabetes and pre-diabetes markets, projected to reach nearly $59 billion and over $50 billion, respectively, by 2025.

Nemaura Medical (NASDAQ: NMRD) officially launched its BEAT®diabetes program on Dec. 17, 2020, which includes the proBEAT™ monitor—an innovative, non-invasive glucose monitoring patch. This device provides real-time glucose feedback and personalized insights via a smartphone app, aiming to assist users in managing diabetes and promoting weight loss. Supported by AI technology, users receive continuous coaching through a virtual assistant named Lena. The company operates within the rapidly growing diabetes management market, projected to reach nearly $59 billion by 2025.

On December 11, 2020, Nemaura Medical, Inc. (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will present a corporate overview at the 13th Annual LD Micro Main Event virtual investor conference on December 15 at 8:00 AM PST/11:00 AM EST. The presentation will last 10 minutes, followed by a Q&A session. Nemaura focuses on developing non-invasive wearable diagnostic devices, including sugarBEAT^®, a glucose monitor that received CE mark approval. The company has submitted a PMA for sugarBEAT^® to the U.S. FDA, targeting the growing diabetes and health-tech markets.

Summary not available.

Nemaura Medical, Inc. (NASDAQ: NMRD) announced its financial results for Q2 2020, reporting a net loss of $1.58 million, an increase from $1.12 million in Q2 2019. The company has submitted a PMA application for its sugarBEAT® device to the FDA and plans to launch proBEAT™, a non-invasive glucose monitor, in the U.S. in December 2020. Nemaura recently in-licensed rights to a digital weight management program and completed an $11.5 million public offering. The company aims to address the needs of 113 million diabetic and pre-diabetic patients in the U.S. alone.